Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Janet Gammon"'
Autor:
Sylvain Baruchel, Ira J. Dunkel, Douglas Strother, Mark Kowalski, Janet Gammon, Lia Gore, Kenneth J. Cohen, John F. Kuttesch, Stewart Goldman, David N. Korones, Jeffrey C. Allen, Amy Smith, Johannes E. A. Wolff, Ute Bartels, Michal Yalon, Eric Bouffet, Stephen Gilheeney, Roger J. Packer
Publikováno v:
Neuro-Oncology. 16:1554-1559
The prognosis of diffuse intrinsic pontine glioma (DIPG) remains poor, with no drug proven to be effective.Patients with clinically and radiologically confirmed, centrally reviewed DIPG, who had failed standard first-line therapy were eligible for th
Autor:
Giselle L. Sholler, Sylvain Baruchel, Meredith S. Irwin, Yvan Samson, Bing Wu, Janet Gammon, Daniel A. Morgenstern, Rosanna Yankanah, Ute Bartels, Monia Marzouki
Publikováno v:
Pediatric Blood & Cancer. 61:128-133
Background The combination of vinblastine and mammalian target of rapamycin (mTOR) inhibitor sirolimus inhibits the growth of neuroblastoma xenografts through pro-apoptotic and anti-angiogenic mechanisms. This phase I study aimed to explore the safet
Autor:
Mark T. Greenberg, Deborah Tomlinson, Janet Gammon, Lillian Sung, Eric Bouffet, Ute Bartels, Hilary A. Llewellyn-Thomas, Dean A. Regier, Pamela S. Hinds, Jocelyne Volpe, Sylvain Baruchel, Maru Barrera
Publikováno v:
Canadian Medical Association Journal. 183:E1252-E1258
Background: The choice between palliative chemotherapy (defined as the use of cytotoxic medications delivered intravenously for the purpose of our study) and supportive care alone is one of the most difficult decisions in pediatric oncology, yet litt
Autor:
Sylvain Baruchel, Janet Gammon, Darren Hargrave, Albert Moghrabi, M. Diezi, Max J. Coppes, Eric Bouffet, Conrad V. Fernandez, Diana Stempak
Publikováno v:
European Journal of Cancer. 42:2335-2342
The aims of this study were to determine the maximum tolerated dose (MTD), toxicity and pharmacokinetics of oral temozolomide administered over 42 d in children with recurrent/refractory brain tumours. Cohorts of 3-6 patients were treated for 42 d, f
Autor:
Deborah Tomlinson, Eric Bouffet, Sylvain Baruchel, Lillian Sung, Michael Capra, Pamela S. Hinds, Maru Barrera, Hilary A. Llewellyn-Thomas, Janet Gammon, Mark L. Geenberg, Jocelyne Volpe
Publikováno v:
European Journal of Oncology Nursing. 10:198-206
The ultimate aim of our research program is to provide strategies that facilitate parental decision-making for parents of children with cancer receiving end-of-life care. As a first step to develop this program, we needed insight into parents' reacti
Autor:
Bonnie Stevens, Mark S. Greenberg, Janet Yamada, Madelyn Beamer, Patricia McKeever, Amiram Gafni, Stacey Daub, Marilyn Booth, Janet Gammon
Publikováno v:
Health and Social Care in the Community. 12:142-149
The goal of this study was to determine the perspectives of healthcare professionals (HPs) from community and hospital settings involved in a paediatric home chemotherapy programme. Using a prospective descriptive study design, HPs including paediatr
Publikováno v:
Clinical Pharmacology & Therapeutics. 72:490-497
Background and Objective Celecoxib is a member of a novel group of agents that selectively inhibit cyclooxygenase 2 (COX-2). COX-2 inhibitors have emerged as an important class of drugs because of the lower incidence of side effects when compared wit
Autor:
Ron M. Grant, Nauman Tariq, Darren R. Hargrave, Sylvain Baruchel, Eric Bouffet, R N Janet Gammon
Publikováno v:
Cancer. 95:1294-1301
BACKGROUND Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. METHODS Patients younge
Autor:
Gideon Koren, Janet Gammon, Jacqueline Halton, Martin A. Champagne, Diana Stempak, Sylvain Baruchel
Publikováno v:
Clinical Pharmacology & Therapeutics. 77:226-228
Autor:
Daniel A, Morgenstern, Monia, Marzouki, Ute, Bartels, Meredith S, Irwin, Giselle L S, Sholler, Janet, Gammon, Rosanna, Yankanah, Bing, Wu, Yvan, Samson, Sylvain, Baruchel
Publikováno v:
Pediatric bloodcancer. 61(1)
The combination of vinblastine and mammalian target of rapamycin (mTOR) inhibitor sirolimus inhibits the growth of neuroblastoma xenografts through pro-apoptotic and anti-angiogenic mechanisms. This phase I study aimed to explore the safety and toxic